I first read about GLP-1 receptor agonists recently. They are diabetes drugs.
However, I immediately thought that they would be a great thing to try for Parkinson's.
Why? Because GLP 1 receptor agonists can lower inflammation, calm microglial cells, and reduce programmed cell death.
Well, it turned out that the Cure Parkinson's organization already has been investigating this class of drugs for benefits to people with Parkinson's.
So far, there are three existing drugs in the GLP-1R agonist class. They are called liraglutide, lixisenatide, and exenatide. This study is about exenatide. All three of these drugs are delivered by injection. (Bydureon is just a form of exenatide that you only have to take once a week, instead of daily.)
“This is a very promising finding, as the drug holds potential to affect the course of the disease itself, and not merely the symptoms. With existing treatments, we can relieve most of the symptoms for some years, but the disease continues to worsen.”
-- Professor Tom Foltynie (UCL Institute of Neurology).
LANCET ARTICLE :
Athauda, Dilan, et al. "Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial." The Lancet 390.10103 (2017): 1664-1675.
This is a 2017 article. There are other studies underway. Another GLP-1R agonist, Lixisenatide, may be more effective. There are various things to consider.
Written by
ElliotGreen
To view profiles and participate in discussions please or .
It's been around a while. I participated in a webinar with the trial organisers. Phase 2 finished nearly 2 years ago now and phase 2 trials are under way on other glp1 receptor agonists but the phase 3 for exanatide hasn't even been announced.
Click on the link called "collaboration" (near the top right corner of the webpage), and then click on the link called "Disease-Modifying Therapies in the PD Trial Pipeline (date of last update)".
Here are the two follow-up scientific publications that Simon addressed in the last two articles:
1. Athauda, Dilan, et al. 2019. Post hoc analysis of the Exenatide‐PD trial—Factors that predict response. European Journal of Neuroscience, 49(3), pp.410-421.
"In the subgroup analyses, exenatide once-weekly was associated with broadly improved outcome measures assessing motor severity, non-motor symptoms, cognition and quality of life across all subgroups, however tremor-dominant phenotype and lower MDS-UPDRS Part-2 scores predicted greatest motor response to exenatide and there was an indication that patients with older age of onset and disease duration over 10 years responded less well."
2. Athauda, Dilan, et al. 2019. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the Exenatide-PD trial. JAMA neurology, 76(4), pp.420-429.
Here, they used exosomes from the brain, which circulate in the blood, to examine the effects of the drug in the brain. Very exciting, because it normally hasn't been easy to track the effects of drugs in the brain.
Also, he notes that "some of the investigators involved in the study have ... published an OPEN ACCESS commentary in the Journal of Parkinson’s disease." This was back in 2017, following the publication of the initial results of the phase 2 trial.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Medium-Dose Lithium May Hit Parkinson Disease Targets...
Parkinson disease risks: correctly identifying environmental factors for a chronic disease
New Nrf2 activator drug gets FDA approval for Freidrich ataxia
Shining a light on Protein Aggregation in Parkinson's Disease
Clinical severity in PD is determined by decline in cortical compensation
